Loading company…
Osprey Medical, based in Minnetonka, is developing the CINCOR System to protect kidneys during coronary interventions.
Osprey Medical is developing the CINCOR System, which aims to remove contrast dye from the heart before it reaches the kidneys, to help prevent contrast induced nephropathy (CIN) during coronary interventions. The company is based in Minnetonka, US, and is listed at Series B stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in